| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Esophageal squamous cell carcinoma (ESCC) is an aggressive form of cancer. Surgery and combined therapies, such as chemotherapy, radiotherapy, or synchronous chemoradiotherapy, have significantly developed in the past several years. To improve the survival rate of ESCC, identifying new markers to predict efficacy of preoperative chemotherapy and/or irradiation is urgently needed. The aim of this study is to identify differences in gene expression and epigenetic alterations between between responders and non-responders who have received neoadjuvant chemotherapy or chemoradiotherapy before esophagectomy for ESCC. We performed integrative transcriptomics by RNA sequencing and methylome sequencing by methyl-DNA immunoprecipitation (MeDIP) analysis. We found genes whose expression levels were different between responders and non-responders; however, there was no difference in their DNA methylation levels between responders and non-responders.
|
